Efficacy and safety of current treatment options for peripheral retinal haemangioblastomas: a systematic review
- PMID: 33834636
- DOI: 10.1111/aos.14865
Efficacy and safety of current treatment options for peripheral retinal haemangioblastomas: a systematic review
Abstract
Importance: Approximately twenty per cent of Von Hippel-Lindau patients with retinal haemangioblastomas (RH) suffer from visual impairment. Various treatment options are available for peripheral RH. However, management of peripheral RH is complex due to multifocality and bilaterality.
Objective: To summarize published evidence on efficacy and safety of different interventions for peripheral RH and to provide treatment recommendations for specialists.
Evidence review: Comprehensive searches were performed using Medline, Embase, Web of Science and Google Scholar database on 4 March 2020. English publications that described outcomes related to efficacy or complications in at least two patients with peripheral RH were included. Efficacy and safety were estimated by complete tumour eradication rate, pretherapeutic and treatment-related complication rate. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to calculate the risk estimate of complications between treatment options.
Findings: Twenty-seven articles were included in this review describing nine different treatment options for peripheral RH: laser photocoagulation (n = 230), cryotherapy (n = 50), plaque radiotherapy (n = 27), vitreoretinal surgery (n = 88), photodynamic therapy (PDT; n = 14), transpupillary thermotherapy (TTT; n = 10), external beam radiotherapy (n = 3), systemic treatment (n = 7) and intravitreal anti-VEGF (n = 2). Complete tumour eradication was achieved in 86.7% (95% CI: 83.5-89.9%) of all eyes. For the different treatments, this was after laser photocoagulation 89.9% (86.1-93.7%), cryotherapy 70.2% (57.0-83.4%), plaque radiotherapy 96.3% (89.1-100.0%), vitreoretinal surgery (100.0%), PDT 64.3% (38.3-90.3%) and TTT 80.0% (53.8-100.0%). No complete tumour eradication was achieved after systemic therapy, external beam radiotherapy or intravitreal anti-VEGF. Photodynamic therapy and vitreoretinal surgery showed the highest complication rate after treatment compared to the other treatments (OR 10.5 [95% CI: 2.9-38.4]) and (OR 5.9 [95% CI: 3.4-9.9]), respectively. Cases that had pretherapeutic complications showed a higher treatment-related complication rate (OR 14.8 [95% CI: 7.3-30.0]) than cases without complications before treatment.
Conclusions and relevance: These findings suggest that laser photocoagulation is the safest and most effective treatment method for peripheral RH up to 1.5 mm in diameter. Vitreoretinal surgery has the highest success rate for complete tumour eradication and may be the most suitable treatment option in the presence of pretherapeutic complications and for larger tumours.
Keywords: Benign tumours; haemangioblastoma; retina; von Hippel-Lindau.
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Similar articles
-
[Retinal hemangioblastoma: Treatment strategy and long-term follow-up in a retrospective cohort].J Fr Ophtalmol. 2018 Feb;41(2):164-169. doi: 10.1016/j.jfo.2017.07.004. Epub 2017 Dec 28. J Fr Ophtalmol. 2018. PMID: 29290462 French.
-
Therapeutic outcomes of retinal hemangioblastomas.Retina. 2014 Dec;34(12):2479-86. doi: 10.1097/IAE.0000000000000254. Retina. 2014. PMID: 25072649
-
Long-Term Therapeutic Outcomes of Photodynamic Therapy-Based or Photocoagulation-Based Treatments on Retinal Capillary Hemangioma.Photomed Laser Surg. 2018 Jan;36(1):10-17. doi: 10.1089/pho.2017.4296. Epub 2017 Oct 25. Photomed Laser Surg. 2018. PMID: 29068750
-
[Capillary hemangioma of the retina in cases of von Hippel-Lindau syndrome. New therapeutic directions].Ophthalmologe. 2007 Feb;104(2):114-8. doi: 10.1007/s00347-007-1485-1. Ophthalmologe. 2007. PMID: 17256181 Review. German.
-
[Retinal angiomatosis].Klin Monbl Augenheilkd. 2005 Feb;222(2):90-109. doi: 10.1055/s-2005-857911. Klin Monbl Augenheilkd. 2005. PMID: 15719313 Review. German.
Cited by
-
Hyper-reflective retinal foci as possible in vivo imaging biomarker of microglia activation in von Hippel-Lindau disease.PLoS One. 2022 Aug 12;17(8):e0272318. doi: 10.1371/journal.pone.0272318. eCollection 2022. PLoS One. 2022. PMID: 35960779 Free PMC article.
-
Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.J Vitreoretin Dis. 2024 Dec 31:24741264241309684. doi: 10.1177/24741264241309684. Online ahead of print. J Vitreoretin Dis. 2024. PMID: 39744647 Free PMC article.
-
Novel Surgical Treatment of an Intraretinal Juxtapapillary Hemangioblastoma Using Intraocular Diathermy Forceps: A Case Report.Case Rep Ophthalmol. 2023 Oct 16;14(1):546-554. doi: 10.1159/000530687. eCollection 2023 Jan-Dec. Case Rep Ophthalmol. 2023. PMID: 37901641 Free PMC article.
-
The rare diagnosis of Von Hippel-Lindau disease in a 29-year-old patient.Oman J Ophthalmol. 2024 Jun 27;17(2):287-290. doi: 10.4103/ojo.ojo_161_22. eCollection 2024 May-Aug. Oman J Ophthalmol. 2024. PMID: 39132100 Free PMC article. No abstract available.
-
Research trends and hotspots of laser therapy in hemangioma: a bibliometric and visualization analysis.Lasers Med Sci. 2025 Feb 21;40(1):107. doi: 10.1007/s10103-025-04312-2. Lasers Med Sci. 2025. PMID: 39979455 Free PMC article. Review.
References
-
- Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP & Myles R (2005): Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol 123: 328-332.
-
- Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gómez de las Heras K & Botella LM (2017): Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis 12: 122.
-
- Avci R, Yilmaz S, Inan UU, Kaderli B & Cevik SG (2017): Vitreoretinal surgery for patients with severe exudative and proliferative manifestations of retinal capillary hemangioblastoma because of von hippel-lindau disease. Retina 37: 782-788.
-
- Binderup MLM, Stendell AS, Galanakis M, Moller HU, Kiilgaard JF & Bisgaard ML (2018): Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol 102: 942-947.
-
- Blodi CF, Russell SR, Pulido JS & Folk JC (1990): Direct and feeder vessel photocoagulation of retinal angiomas with dye yellow laser. Ophthalmology 97: 791-797.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources